ArticleSignal transduction and targeted therapy2025

Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial.

Marion Thibaudin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.